ClinVar Miner

Submissions for variant NM_000257.4(MYH7):c.976G>C (p.Ala326Pro)

gnomAD frequency: 0.00010  dbSNP: rs372731424
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 13
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine RCV000766416 SCV000059667 uncertain significance not provided 2019-04-05 criteria provided, single submitter clinical testing The p.Ala326Pro variant has been reported in 3 individuals with HCM (Michels 2009, D'Argenio 2014, LMM data). It has been identified in 19/126594 European chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org/; dbSNP rs372731424). Clinvar: VUS (GeneDx, Invitae, CSER). Furthermore, alanine (Ala) at position 326 is not conserved in mammals or evolutionarily distant species, and the change to proline (Pro) was predicted to be benign using a computational tool clinically validated by our laboratory. This tool's benign prediction is estimated to be correct 89% of the time (Jordan 2011). In summary, due to conflicting data, the clinical significance of the p.Ala326Pro variant is uncertain.
CSER _CC_NCGL, University of Washington RCV000148710 SCV000190440 uncertain significance Primary familial hypertrophic cardiomyopathy 2014-06-01 criteria provided, single submitter research Low GERP score may suggest that this variant may belong in a lower pathogenicity class
GeneDx RCV000766416 SCV000208712 uncertain significance not provided 2018-12-03 criteria provided, single submitter clinical testing The A326P variant of uncertain significance in the MYH7 gene has been reported in association with HCM (Michels et al., 2009; D'Argenio et al, 2014; Homburger et al., 2016; Walsh et al., 2017). Michels et al. (2009) identified A326P in two unrelated probands with HCM as well as in two asymptomatic relatives, who had mild evidence of HCM upon clinical evaluation. A326P was also identified in an individual diagnosed with HCM shortly after birth, who harbored additional variants in the MYH7 and INS-IGF2 genes (D'Argenio et al, 2014). The A326P variant was inherited from the proband's clinically unaffected father (D'Argenio et al, 2014). This variant has also been identified, both independently and in conjunction with additional cardiogenetic variants, in other unrelated individuals referred for cardiomyopathy genetic testing at GeneDx; segregation data are limited or absent due to the lack of clinical information provided and/or insufficient participation by informative family members.The A326P variant is observed in 19/126,594 (0.015%) alleles from individuals of European (non-Finnish) ancestry in large population cohorts (Lek et al., 2016). A326P is a semi-conservative amino acid substitution, which may impact secondary protein structure as these residues differ in some properties. In addition, this variant is located in the myosin motor domain, a region enriched with missense variants reported in association with HCM (Walsh et al., 2017; Kelly et al., 2018). However, in-silico analyses, including protein predictors and evolutionary conservation, support that this variant does not alter protein structure/function.Therefore, based on the currently available information, it is unclear whether this variant is pathogenic or benign.
Invitae RCV000227951 SCV000284300 uncertain significance Hypertrophic cardiomyopathy 2022-10-07 criteria provided, single submitter clinical testing This sequence change replaces alanine, which is neutral and non-polar, with proline, which is neutral and non-polar, at codon 326 of the MYH7 protein (p.Ala326Pro). This variant is present in population databases (rs372731424, gnomAD 0.02%). This missense change has been observed in individual(s) with hypertrophic cardiomyopathy (PMID: 19666645, 24183960, 27247418, 27532257, 31513939). ClinVar contains an entry for this variant (Variation ID: 43117). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt MYH7 protein function. This variant is found within a region of MYH7 between codons 181 and 937 that contains the majority of the myosin head domain. Missense variants in this region have been shown to be significantly overrepresented in individuals with hypertrophic cardiomyopathy (PMID: 27532257). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Center for Human Genetics, University of Leuven RCV000227951 SCV000886831 uncertain significance Hypertrophic cardiomyopathy 2018-10-31 criteria provided, single submitter clinical testing
Fulgent Genetics, Fulgent Genetics RCV000763914 SCV000894855 uncertain significance Hypertrophic cardiomyopathy 1; Myopathy, myosin storage, autosomal recessive; Myosin storage myopathy; Congenital myopathy with fiber type disproportion; Dilated cardiomyopathy 1S; MYH7-related skeletal myopathy 2018-10-31 criteria provided, single submitter clinical testing
Blueprint Genetics RCV000766416 SCV000928253 uncertain significance not provided 2019-02-27 criteria provided, single submitter clinical testing
Mendelics RCV000778404 SCV001139417 uncertain significance Hypertrophic cardiomyopathy 1 2019-05-28 criteria provided, single submitter clinical testing
Illumina Laboratory Services, Illumina RCV003320095 SCV001266435 uncertain significance Myosin storage myopathy 2017-09-06 criteria provided, single submitter clinical testing This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). No publications were found based on this search. Allele frequency data from public databases did not allow this variant to be ruled in or out of causing disease. Therefore, this variant is classified as a variant of unknown significance.
Color Diagnostics, LLC DBA Color Health RCV001187131 SCV001353817 uncertain significance Cardiomyopathy 2023-11-20 criteria provided, single submitter clinical testing This missense variant replaces alanine with proline at codon 326 of the MYH7 protein. Computational prediction is inconclusive regarding the impact of this variant on protein structure and function. To our knowledge, functional studies have not been reported for this variant. This variant has been reported in individuals affected with hypertrophic cardiomyopathy (PMID: 19666645, 24183960, 27247418, 27476098, 27532257, 30696458, 31323898, 32369506, 33495597, 37466024) and in an individual affected with noncompaction cardiomyopathy (PMID: 29447731). A family member of one proband was a healthy carrier (PMID: 24183960). This variant has also been identified in 25/282608 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance.
CHEO Genetics Diagnostic Laboratory, Children's Hospital of Eastern Ontario RCV001187131 SCV002042707 uncertain significance Cardiomyopathy 2021-12-08 criteria provided, single submitter clinical testing
Genetics and Molecular Pathology, SA Pathology RCV000778404 SCV002761854 uncertain significance Hypertrophic cardiomyopathy 1 2021-12-01 criteria provided, single submitter clinical testing
Ambry Genetics RCV003162310 SCV003913558 uncertain significance Cardiovascular phenotype 2021-05-06 criteria provided, single submitter clinical testing The c.976G>C (p.A326P) alteration is located in exon 11 (coding exon 9) of the MYH7 gene. This alteration results from a G to C substitution at nucleotide position 976, causing the alanine (A) at amino acid position 326 to be replaced by a proline (P). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.